Not all controls are made equal: Definition of human kidney reference samples by single cell gene expression profiles

Competing Interest Statement

Identifying kidney disease mechanisms often requires comparing samples from disease states with healthy reference tissues. However, the effect of variations in sample procurement, storage and donor baseline characteristics of reference samples has thus far not been evaluated. Three distinct kidney reference sample types were evaluated for integrity and injury biomarkers and in their ability to define differentially expressed genes (DEGs) when compared to three different diabetic kidney disease (DKD) states. Unaffected parts of tumor nephrectomies (TN), pre-transplant living donor biopsies (LD), and percutaneous kidney biopsies from healthy volunteers (HC) served as sources for reference tissue. Single cell gene expression profiles showed differences in the expression of injury or disease markers and the proportion of immune and proximal cell states. TN exhibited the highest expression of early stress response genes. A gene set associated with procurement effect in post-operative biopsies (LD and TN) was identified. An age-associated transcriptional signature was extracted from the reference data. Controlling for age and tissue procurement effects, immune-related pathways were found to be most enriched in DKD when compared to HC. Energy-related processes were enriched in DEGs from DKD versus LD. TN samples exhibited more underlying pathology than LD. The pathway analyses using the DEGs underscore the importance of accounting for appropriate confounding factors in differential expression analyses between disease and reference samples.

Funding Statement

The study is funded by the following grants from the NIH: The KPMP is funded by the following grants from the NIDDK: U01DK133081, U01DK133091, U01DK133092, U01DK133093, U01DK133095, U01DK133097, U01DK114866, U01DK114908, U01DK133090, U01DK133113, U01DK133766, U01DK133768, U01DK114907, U01DK114920, U01DK114923, U01DK114933, U24DK114886, UH3DK114926, UH3DK114861, UH3DK114915, UH3DK114937. Additional funding sources are K23 DK116720, R01 DK132399, UC2 DK114886, and P30 DK116073, JDRF (2-SRA-2019-845-S-B, 3-SRA-2022-1097-M-B), the Boettcher Foundation, and in part by the Intramural Research Program at NIDDK and the Centers for Disease Control and Prevention (CKD Initiative) under inter-agency agreement #21FED2100157DPG (P.B), U54DK083912, P30 DK081943/HCA: Kidney Seed Network (M.K), U2C DK114886, R21 DK126329 and Chan-Zuckerberg Foundation - CZF2019-002447 (M.B.), K23 DK125529 (A.S.N). This work was also supported by the George M. OBrien Michigan Kidney Translational Resource Center funded by NIH/NIDDK grant U54DK137314.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The KPMP study was approved by the IRB of the University of Washington, the IMPROVE-T2D and RENAL HEIR and CROCODILE studies were approved by the IRB of the University of Colorado, the PRECISE cohort and the Human Kidney Transplant Transcriptomic Atlas studies were approved by the IRB of the University of Michigan.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes